Alzheimer's disease is on the rise, but researchers such as Dr. Michael Devous expect the numbers to shift into reverse.
"I think we're going to cure Alzheimer's disease, and we're not far away from it," said Devous, a professor and director of the NeuroImaging Core for the Alzheimer's Disease Center at the University of Texas Southwestern Medical Center. "Ten years ago I didn't think so, but we've made tremendous progress. … We haven't cured anyone from this disease yet, but I'm hopeful that the trials we've started will change the course of this disease in a positive way."
It's a rare burst of good news for this specific disease. According to an April study published in the New England Journal of Medicine, Alzheimer's, the most common form of dementia or memory loss that typically worsens over time, is now the nation's sixth-leading cause of death.
It has surpassed cancer and heart disease as the costliest disease, affecting more than 5.4 million Americans, with about 4.1 million requiring intensive care that totals $200 billion a year. Patients live an average of four to eight years after an Alzheimer's diagnosis, but some live as long as 20 years, with 75 percent of those with Alzheimer's going to a nursing home by age 80.
Current treatments may temporarily ease symptoms but don't slow the disease, which can lead to patients losing recognition of loved ones, the ability to speak or recall the names for objects and mastery of simple life skills.
Researchers, however, find hope in three promising approaches: healthful lifestyle changes, genetic testing to identify those at higher risk and removal of amyloid plaque.
While the precise role of plaque is still being studied, it's known that these deposits of apparently toxic protein peptide settle between the brain's nerve cells and are found disproportionately in people with Alzheimer's, according to the National Institutes of Health's National Institute on Aging.
Adding to the optimism is the Texas Alzheimer's Research and Care Consortium, which pools efforts from Texas institutions. For Devous, the game-changer came last year with the Food and Drug Administration's approval of Amyvid, an amyloid imaging agent that allows researchers to track plaque in positron emission tomography scans. So far, he has learned that plaque removal doesn't help those in advanced stages of Alzheimer's, probably because at that point, the plaque has done irreversible damage.